Close Menu

CYP2C19

The new distribution partnership is for the US acute care market where, until now, Spartan was selling directly.

Spartan's test is for the rapid, near-patient determination of a cardiac patient's genotype for aid in determining appropriate antiplatelet treatment.

Operating since the beginning of the year in a pilot mode, the company officially launched its comprehensive PGx testing service last week.

The latest analysis of CYP2C19 genotyping to guide antiplatelet therapy tries to address cost questions from the vantage of a payor or large healthcare system.

The investment will fund the research and development of new diagnostic testing products, including rapid genetic testing.

NEW YORK (GenomeWeb) – Health Canada has approved Spartan Bioscience's non-invasive genetic test for determining within an hour whether a person has CYP2C19 genetic mutations.

A study led by researchers from Brigham and Women's Hospital on the effect of CYP2C19 testing on physicians' prescribing patterns has found that when doctors received patient test results for genetic markers associated with clopidogrel response through a pharmacy-benefit manager-

This article has been updated to note that PDI is moving away from the contract sales business with drug companies. Originally published Oct. 22.

Having published research last year identifying a novel haplotype that may alter the interpretation of CYP2C19 genotyping, clinical researchers from the Icahn School of Medicine at Mount Sinai in New York have now published a paper describing an allele-specific PCR assay to detec

Canadian molecular diagnostics developer Spartan Bioscience said this week that the US Food and Drug Administration has granted 510(k) clearance to the Spartan RX CYP2C19 assay.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.